Tekla Total Current Liabilities from 2010 to 2024
| HQH Stock | USD 17.43 0.03 0.17% |
Total Current Liabilities | First Reported 1996-03-31 | Previous Quarter 1.1 M | Current Value 1.1 M | Quarterly Volatility 6.8 M |
Check Tekla Healthcare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Healthcare's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 0.0 or Selling General Administrative of 2.5 M, as well as many indicators such as Price To Sales Ratio of 113, Dividend Yield of 0.0246 or PTB Ratio of 0.58. Tekla financial statements analysis is a perfect complement when working with Tekla Healthcare Valuation or Volatility modules.
Tekla | Total Current Liabilities |
Latest Tekla Healthcare's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Tekla Healthcare Investors over the last few years. Total Current Liabilities is an item on Tekla Healthcare balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Tekla Healthcare Investors are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Tekla Healthcare's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Healthcare's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Tekla Total Current Liabilities Regression Statistics
| Arithmetic Mean | 6,410,593 | |
| Geometric Mean | 2,349,256 | |
| Coefficient Of Variation | 140.44 | |
| Mean Deviation | 6,382,566 | |
| Median | 1,321,007 | |
| Standard Deviation | 9,003,206 | |
| Sample Variance | 81.1T | |
| Range | 33.7M | |
| R-Value | (0.03) | |
| Mean Square Error | 87.2T | |
| R-Squared | 0 | |
| Significance | 0.90 | |
| Slope | (68,013) | |
| Total Sum of Squares | 1134.8T |
Tekla Total Current Liabilities History
About Tekla Healthcare Financial Statements
Investors use fundamental indicators, such as Tekla Healthcare's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Tekla Healthcare's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 1.3 M | 1.3 M |
Currently Active Assets on Macroaxis
When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:Check out the analysis of Tekla Healthcare Correlation against competitors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.145 | Dividend Share 1.66 | Earnings Share 1.31 | Revenue Per Share 0.197 | Quarterly Revenue Growth (0.06) |
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.